Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon. [electronic resource]
Producer: 19980407Description: 6-12 p. digitalISSN:- 0556-6177
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Carcinoma, Renal Cell -- secondary
- Drug Administration Schedule
- Female
- Fever -- chemically induced
- Humans
- Hypotension -- chemically induced
- Immunologic Factors -- administration & dosage
- Infusions, Intravenous
- Injections, Subcutaneous
- Interferon-alpha -- administration & dosage
- Interleukin-2 -- administration & dosage
- Kidney Neoplasms -- pathology
- Male
- Melanoma -- secondary
- Middle Aged
- Recombinant Proteins -- administration & dosage
- Skin Neoplasms -- pathology
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.